Modern Slavery and Human Trafficking Statement for the year ending 31st December 2016

Overview

Mundipharma International Limited is committed to operating in an ethical and transparent manner. In line with that commitment we have incorporated the requirements of the Modern Slavery Act 2015 (the “Act”) into our Code of Business Ethics and our compliance framework.

We take the upholding of these high standards seriously and do not tolerate slavery or human trafficking within our organisation or from those whom we buy products or services.

Due to the nature of our business, we currently consider ourselves to be at low risk of exposure to slavery and human trafficking and are not aware of any areas in our operations likely to lead to a breach of human rights and modern slavery laws. Yet, we remain committed to never knowingly dealing with any organisation connected to slavery or human trafficking.

Training, Communication and Raising Concern

We aim to equip those employees who are involved in procurement activities, with both the knowledge and understanding of the importance of the Act and the role it plays in helping to eradicate modern slavery and trafficking. Specific training of key personnel has been implemented and will be rolled out to all relevant employees and will also be included as part of our induction process for new employees through our Code of Business Ethics.

We encourage open and frank two-way communication and our employees are required to raise any concerns of known or suspected violations of its Code of Business Ethics or of illegal or unethical business conduct. Any such concern can be raised in confidence without fear of retaliation, by approaching Management, HR, Legal or Compliance. Alternatively, individuals may report their concern, and if desired remain anonymous, through our independent Compliance and Ethics Hotline, which is available 24 hours a day.

Any concern raised will be fully investigated and acted upon as appropriate.

Employment Practices

Our employment practices are compliant with applicable employment and health and safety legislation, and as a result, we are confident that there is no slavery or human trafficking taking place within our organisation. Furthermore, we shall ensure that the employment agencies that we deal with are also fully compliant with the applicable legislation.

Due Diligence

We aim not to work with any supplier that we suspect is connected in any way with slavery or human trafficking. As part of our compliance programme, we take steps to assure ourselves that we only partner with third parties that are fit and proper. This process has now been broadened to include screening for any potential or confirmed issues relating to slavery and or human trafficking.
In addition to pre-contract due diligence, any new contracts will require suppliers to ensure all goods and services are provided to Mundipharma International Limited in accordance with all applicable laws, including the Act. No contracts will be awarded to any supplier not able to comply fully with the Act.

For existing suppliers, we are reviewing and updating contracts, as required, to include relevant clauses relating to slavery and human trafficking.

**Enforcement**

Any suspected breach of our compliance programme or of our Code of Business Ethics, including the Act, will be investigated and such investigations could lead to the termination of supplier contracts.

**Conclusion**

Mundipharma International Limited is not aware of any slavery or human trafficking taking place in its business or within the businesses of its suppliers. Mundipharma International Limited will continue to apply appropriate risk-based due diligence processes as it further embeds the Act into its compliance programme.

This Statement is made pursuant to section 54 of the Act and constitutes the Modern Slavery and Human Trafficking Statement for the Financial Year ended 31st December 2016 for Mundipharma International Limited.

This Statement was approved by the Board of Mundipharma International Limited on 29th June 2017.

David Silver  
Chief Financial Officer